Acta Scientific Pharmaceutical Sciences (ISSN: 2581-883X)

Mini Review Volume 4 Issue 7

A Minireview on Pandemic Novel COVID-19

V Anilkumar*

Assistant Professor, Department of Pharmaceutical Technology, GIET School of Pharmacy, Rajamahendravaram, East Godavari, Andhra Pradesh, India

*Corresponding Author: V Anilkumar, Assistant Professor, Department of Pharmaceutical Technology, GIET School of Pharmacy, Rajamahendravaram, East Godavari, Andhra Pradesh, India.

Received: May 26, 2020; Published: June 30, 2020



Human history is observing a very strange time fighting an invisible enemy, the novel COVID-19 coronavirus. initially observed in the Wuhan province of China, now vastly spreading around the world. The Pandemic which COVID-19 has made on the Globe needs no depiction. The virus has been accounted for to be affecting the lungs and related respiratory tracts promoting harm of the alveoli. It has been accounted the respiratory sickness is the prevailing Clinical indication of COVID-19. This review article discussed for an easily understanding of the causes, different type of Human viruses regarded of Coronavirus, clinical diagnosis of RT-PCR, Primary prevention and control of the virus. Therefore, this review article main theme is focusing on more research work to be carried out to provide more reliable and valid effect to control and mange public emergency in both acute and chronic conditions of coronavirus.

Keywords: COVID-19; Pandemic; RT-PCR; Prevention; Respiratory



  1. Lu R., et al. “Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origin and receptor binding”. Lancet 10224 (2020): 565-574.
  2. “Coronavirus disease (COVID-19) situation reports” (2020).
  3. Riou J and Althaus CL. “Pattern of early human- to- human transmission of a Wuhan 2019 coronavirus (2019-ncoV), December 2019 to January 2020”. Eurosurveillance4 (2020): 2000058.
  4. Liu Y., et al. “The reproductive number of COVID-19 is higher compared to SARS coronavirus”. Journal of Travel Medicine (2020).
  5. "2019 Novel coronavirus (2019-ncoV)". Centres for Disease control and prevention (2020).
  6. Geller C., et al. “Human coronavirus: insights into environmental resistance and its influence on the development of new antiseptic strategies". Viruses11 (2012): 3044-3068.
  7. Michael J Loeffelholz and Yi-wei Tang. “Laboratory diagnosis of emerging human coronavirus infections- the state of the art”.
  8. Shereen MA., et al. “COVID-19 Infection: origin, Transmission and characteristics of Human Coronavirus”. Jade Women Red Flats 24 (2020): 91-98.
  9. Maier HJ and Bickeprevention Britton P. “Coronavirus: methods and protocols, coronavirus method protective” (2015): 1-282.
  11. , et al. “A review of COVID-19 (coronavirus disease-2019) diagnosis, treatment and prevention” 4.2 (2020): 116-125.
  12. Signal T. “A Review of coronavirus diseases-2019 (COVID-19)”. Indian Journal of Pediatrics 4 (2020): 281-286.
  14. , et al. “COVID-19: An overview”. WJPR 9 (2020): 1810-1827.
  15. Maharshi Malakar." Coronavirus- A review article”. Acts Scientific Dental Sciences5 (2020): 10-12.
  16. Jiancheng Z., et al. “Current status of Potential therapeutic candidates for the COVID-19 Crisis”. Brain, Behavior, and Immunity 87 (2020): 59-73.
  17. Yung F T., et al. “A Review of SARS- CoV-2 and the ongoing Trails”. International Journal of Molecular Sciences 21 (2020): 2657.
  18. Dayal D and Gupta S. “Connecting BCG vaccination and COVID-19: Additional Data”. Med Rxiv (2020).
  19. 2
  20. , et al. “Coronavirus (COVID-19): Clinical features, diagnosis and treatment 9.5 (2020).
  21. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 49740.
  22. W Guan., et al. “Clinical characteristics of Coronavirus Diseases 2019 in China”.
  23. Richman DD., et al. “Clinical virology, 4th edition”. Washington: ASM Press (2016).
  24. Garner JS., et al. “CDC definitions of nosocomial infections”. American Journal of Infection Control 16 (1988): 128-140.


Citation: V Anilkumar. “A Minireview on Pandemic Novel COVID-19".Acta Scientific Pharmaceutical Sciences 4.7 (2020): 19-24.


Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor1.197

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US